Can Lp(a) become the next A1C? A case for digital health management tools to overcome inertia to Lipoprotein (a) testing
Despite its known correlations with risk of cardiovascular disease, awareness and testing for Lipoprotein (a) lags that of other serological markers with estimates that less than 1% of the US population have undergone screening. Herein we outline how digital tools framed around motivational models (...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2025.1545787/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860426127966208 |
|---|---|
| author | Christof Wedemeyer Martin Peters Graham Jones Graham Jones |
| author_facet | Christof Wedemeyer Martin Peters Graham Jones Graham Jones |
| author_sort | Christof Wedemeyer |
| collection | DOAJ |
| description | Despite its known correlations with risk of cardiovascular disease, awareness and testing for Lipoprotein (a) lags that of other serological markers with estimates that less than 1% of the US population have undergone screening. Herein we outline how digital tools framed around motivational models (COM-B and SEM), might help increase likelihood of patients seeking Lp(a) testing as part of their managed care. Furthermore, we highlight how recent trends in prescription of GLP-1 receptor antagonists are serving to motivate patients to manage biomarkers related to T2D and obesity, which are also relevant in cardiovascular disease. Capitalizing on this trend to stimulate interest in Lp(a) management could have near term consequence, and with disease modifying therapies in development ultimately improve outcomes in cardiovascular disease. |
| format | Article |
| id | doaj-art-6b20257e6a7e4903bf8ed3632589991b |
| institution | Kabale University |
| issn | 2297-055X |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj-art-6b20257e6a7e4903bf8ed3632589991b2025-02-10T14:22:00ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2025-02-011210.3389/fcvm.2025.15457871545787Can Lp(a) become the next A1C? A case for digital health management tools to overcome inertia to Lipoprotein (a) testingChristof Wedemeyer0Martin Peters1Graham Jones2Graham Jones3Patient Solutions & Services, Novartis Pharma AG, Basel, SwitzerlandPatient Solutions & Services, Novartis Pharma AG, Basel, SwitzerlandData Design & Clinical Innovation, Novartis Pharmaceuticals, Cambridge, MA, United StatesClinical and Translational Science Institute, Tufts University Medical Center, Boston, MA, United StatesDespite its known correlations with risk of cardiovascular disease, awareness and testing for Lipoprotein (a) lags that of other serological markers with estimates that less than 1% of the US population have undergone screening. Herein we outline how digital tools framed around motivational models (COM-B and SEM), might help increase likelihood of patients seeking Lp(a) testing as part of their managed care. Furthermore, we highlight how recent trends in prescription of GLP-1 receptor antagonists are serving to motivate patients to manage biomarkers related to T2D and obesity, which are also relevant in cardiovascular disease. Capitalizing on this trend to stimulate interest in Lp(a) management could have near term consequence, and with disease modifying therapies in development ultimately improve outcomes in cardiovascular disease.https://www.frontiersin.org/articles/10.3389/fcvm.2025.1545787/fullawarenessdigital supportpatient awarenessmotivational toolslipoprotein aprevention |
| spellingShingle | Christof Wedemeyer Martin Peters Graham Jones Graham Jones Can Lp(a) become the next A1C? A case for digital health management tools to overcome inertia to Lipoprotein (a) testing Frontiers in Cardiovascular Medicine awareness digital support patient awareness motivational tools lipoprotein a prevention |
| title | Can Lp(a) become the next A1C? A case for digital health management tools to overcome inertia to Lipoprotein (a) testing |
| title_full | Can Lp(a) become the next A1C? A case for digital health management tools to overcome inertia to Lipoprotein (a) testing |
| title_fullStr | Can Lp(a) become the next A1C? A case for digital health management tools to overcome inertia to Lipoprotein (a) testing |
| title_full_unstemmed | Can Lp(a) become the next A1C? A case for digital health management tools to overcome inertia to Lipoprotein (a) testing |
| title_short | Can Lp(a) become the next A1C? A case for digital health management tools to overcome inertia to Lipoprotein (a) testing |
| title_sort | can lp a become the next a1c a case for digital health management tools to overcome inertia to lipoprotein a testing |
| topic | awareness digital support patient awareness motivational tools lipoprotein a prevention |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2025.1545787/full |
| work_keys_str_mv | AT christofwedemeyer canlpabecomethenexta1cacasefordigitalhealthmanagementtoolstoovercomeinertiatolipoproteinatesting AT martinpeters canlpabecomethenexta1cacasefordigitalhealthmanagementtoolstoovercomeinertiatolipoproteinatesting AT grahamjones canlpabecomethenexta1cacasefordigitalhealthmanagementtoolstoovercomeinertiatolipoproteinatesting AT grahamjones canlpabecomethenexta1cacasefordigitalhealthmanagementtoolstoovercomeinertiatolipoproteinatesting |